Allergy Therapeutics starts dosing peanut allergy vaccine candidate

Allergy Therapeutics

Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its ‘VLP Peanut’ vaccine candidate in peanut-allergic patients on Monday.

Allergy Therapeutics

27 March 2023 15:16:28

Source: Sharecast

The firm said its short-course peanut allergy vaccine was being tested in the phase one ‘PROTECT’ trial.

It said the first-in-human study was focussed on evaluating the safety and tolerability of VLP Peanut in healthy and peanut-allergic adult subjects, while exploring preliminary proof of efficacy.

“Allergy Therapeutics' wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body's immune response by making the peanut allergen resemble an inactive virus,” the company explained in its statement.

Reporting by Josh White for Sharecast.com.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

IWeb is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.